Shanghai Junshi Biosciences
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in Shanghai, China, focusing on the discovery, development, and commercialization of innovative drugs. The company operates in various therapeutic areas, including oncology, metabolic disorders, autoimmune diseases, and neurologic conditions. Junshi's notable products include JS001, a recombinant humanized anti-PD-1 monoclonal antibody marketed as TUOYIR for several cancers, and UBP1211, a biosimilar of Humira currently in Phase I clinical trials for rheumatoid arthritis and related conditions. Additionally, the company is advancing other drug candidates, such as JS002, a monoclonal antibody for hyperlipidemia, and several others in early-phase trials targeting various diseases. Junshi has established collaborations with leading pharmaceutical companies, including Eli Lilly and Merck, to develop therapeutic antibodies and explore new treatment combinations. Founded in 2012, Shanghai Junshi Biosciences is committed to addressing unmet medical needs through its extensive research and development initiatives.
8 past transactions
Ruotuo Bio
Corporate Round in 2023
Ruotuo Bio is a biopharmaceutical company that specializes in the development of drug research for tumors and autoimmune diseases.
Immupeutics Medicine
Seed Round in 2023
Immupeutics Medical Technology Co., Ltd. is a biomedical research company specializing in tumor immunotherapy. The firm is dedicated to the research and development of immune cell therapy drugs targeting various types of tumors. In addition to its primary focus on therapeutic agents, Immupeutics also invests in companion diagnostic technology and immunological multi-omics technology. By integrating these innovative approaches, the company aims to enhance patient outcomes through the provision of advanced immune cell therapies and comprehensive treatment methodologies.
GRIT Biotechnology
Series A in 2021
GRIT Biotechnology, established in 2019 and based in Shanghai, China, specializes in the research and development of Tumor Infiltration Lymphocytes (TIL) immunotherapy for treating solid tumors. The company aims to enhance cancer therapies by focusing on this innovative approach.
Immunophage Biotech
Series A in 2021
Immunophage Biotech, established in 2016, is a Chinese pharmaceutical company dedicated to new drug development. Based in Nanjing, with its R&D center in Shanghai's Pujiang High-Tech Park, the company focuses on creating first-in-class immune-regulating therapies for cancer, autoimmune diseases, and neurodegenerative disorders.
Zhishan Weixin Biotechnology
Series A in 2021
Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.
Coherus Biosciences
Post in 2021
Coherus Biosciences is a biopharmaceutical company focused on developing, manufacturing, and commercializing biologic therapeutics for oncology and inflammatory diseases. Its pipeline includes biosimilars for immunology, ophthalmology, and oncology.
IMPACT Therapeutics
Series C in 2020
IMPACT Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009 and based in Shanghai, China, the company focuses on creating targeted anti-cancer treatments utilizing synthetic lethality. IMPACT Therapeutics is actively engaged in several research and development projects, including a PARP inhibitor, a Wee1 inhibitor, and various novel agents targeting DNA damage response mechanisms and the Hedgehog signaling pathway. Through its commitment to advancing treatment options, IMPACT Therapeutics aims to provide patients with effective and targeted anti-cancer therapies.
Stemirna
Series A in 2020
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.